Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Omnicell Inc Stock Research

OMCL

49.82USD-1.24(-2.43%)Market Closed
Watchlist

Market Summary

USD49.82-1.24
Market Closed
-2.43%

OMCL Alerts

  • Big fall in earnings (Y/Y)

OMCL Stock Price

OMCL RSI Chart

OMCL Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-97.15

Price/Sales (Trailing)

1.82

EV/EBITDA

30.47

Price/Free Cashflow

16

OMCL Price/Sales (Trailing)

OMCL Profitability

EBT Margin

-2.26%

Return on Equity

-1.54%

Return on Assets

-0.78%

Free Cashflow Yield

6.25%

OMCL Fundamentals

OMCL Revenue

Revenue (TTM)

1.2B

Revenue Y/Y

-9.78%

Revenue Q/Q

2.87%

OMCL Earnings

Earnings (TTM)

-23.2M

Earnings Y/Y

-61.95%

Earnings Q/Q

123.01%

Price Action

52 Week Range

46.1191.99
(Low)(High)

Last 7 days

-10.3%

Last 30 days

-12.4%

Last 90 days

-28.9%

Trailing 12 Months

-42.3%

OMCL Financial Health

Current Ratio

2.06

OMCL Investor Care

Shares Dilution (1Y)

2.23%

Diluted EPS (TTM)

-0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for OMCL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
SPEARS JOSEPH BRIAN
sold (taxes)
-5,277
55.55
-95.00
chief accounting officer & svp
2023-09-15
Manley Corey J
sold (taxes)
-3,944
55.55
-71.00
evp&chief legal/admin officer
2023-08-15
SPEARS JOSEPH BRIAN
sold (taxes)
-20,827
64.68
-322
chief accounting officer & svp
2023-08-10
Scott Bruce E
acquired
-
-
115
-
2023-08-10
PARRISH MARK W
acquired
-
-
115
-
2023-07-26
Ghoshal Kaushik
acquired
-
-
2,402
-
2023-07-26
SPEARS JOSEPH BRIAN
acquired
-
-
3,500
chief accounting officer & svp
2023-06-15
Seidelmann Scott Peter
sold (taxes)
-221,878
72.32
-3,068
evp, executive advisor
2023-06-15
SPEARS JOSEPH BRIAN
sold (taxes)
-6,870
72.32
-95.00
chief accounting officer & svp
2023-06-15
Manley Corey J
sold (taxes)
-15,982
72.32
-221
evp&chief legal/admin officer

1–10 of 50

Which funds bought or sold OMCL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
22.8
3,102,000
8,830,000
0.01%
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
210
1,031
-%
2023-08-22
COMERICA BANK
new
-
-
-
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
28.57
328,042
861,939
0.01%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
51.59
1,285,000
2,706,000
0.03%
2023-08-21
OSAIC HOLDINGS, INC.
added
8.59
457,932
1,724,400
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-7.13
573,222
4,023,490
0.01%
2023-08-18
Legato Capital Management LLC
unchanged
-
160,815
789,816
0.11%
2023-08-17
Orion Portfolio Solutions, LLC
added
3.66
86,552
373,507
-%
2023-08-16
Nuveen Asset Management, LLC
reduced
-1.53
4,264,660
22,298,700
0.01%

1–10 of 41

Latest Funds Activity

Are funds buying OMCL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OMCL
No. of Funds

Schedule 13G FIlings of Omnicell

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 11, 2023
vanguard group inc
10.03%
4,532,732
SC 13G/A
Feb 09, 2023
vanguard group inc
9.92%
4,430,315
SC 13G/A
Feb 06, 2023
wellington management group llp
7.34%
3,277,600
SC 13G/A
Jan 23, 2023
blackrock inc.
12.8%
5,728,315
SC 13G/A
Feb 10, 2022
vanguard group inc
10.79%
4,740,493
SC 13G/A
Feb 04, 2022
wellington management group llp
5.76%
2,531,555
SC 13G/A
Jan 27, 2022
blackrock inc.
15.9%
6,983,442
SC 13G/A
Jan 26, 2022
blackrock inc.
15.9%
6,983,442
SC 13G/A
Feb 10, 2021
vanguard group inc
10.62%
4,492,384
SC 13G/A
Feb 05, 2021
blackrock inc.
15.7%
6,663,069
SC 13G/A

Recent SEC filings of Omnicell

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Sep 19, 2023
4
Insider Trading
Sep 11, 2023
SC 13G/A
Major Ownership Report
Aug 17, 2023
4
Insider Trading
Aug 16, 2023
8-K
Current Report
Aug 14, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading
Aug 10, 2023
8-K
Current Report
Aug 04, 2023
10-Q
Quarterly Report
Aug 03, 2023
8-K
Current Report

Peers (Alternatives to Omnicell)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.3B
30.4B
-2.55% -6.78%
28.83
6.04
-1.49% 0.14%
106.8B
31.6B
-4.08% -3.94%
29.45
3.38
1.57% -30.40%
32.5B
2.2B
8.28% 24.72%
60.12
14.55
11.56% 37.20%
MID-CAP
5.4B
526.1M
-12.44% 8.39%
-132.09
10.31
74.86% 6.49%
3.1B
2.5B
-18.38% -32.83%
-0.77
1.22
13.30% 59.30%
2.3B
1.2B
-12.37% -42.27%
-97.15
1.82
-1.77% -138.27%
SMALL-CAP
2.1B
193.8M
-23.50% 16.21%
31.34
10.73
18.78% 144.88%
947.5M
319.4M
-33.36% -29.13%
-6.21
2.97
30.27% 15.64%
279.0M
338.1M
- 128.60%
-2.92
0.83
22.28% 17.91%
138.2M
61.6M
-3.09% -45.27%
-9.63
2.24
-4.03% -105.54%
47.7M
24.5M
-18.18% -19.57%
-3.81
1.95
-24.11% 3.57%
1.3M
6.2M
-81.65% 3.23%
-0.06
0.21
-28.21% -7.22%

Omnicell News

Nasdaq
Oversold Conditions For Omnicell (OMCL).
Nasdaq,
33 hours ago
MarketBeat
Today's Death Cross Stocks.
MarketBeat,
5 days ago
Investor's Business Daily
S&P 500: Airbnb, Blackstone Rally On Invite.
Investor's Business Daily,
18 days ago
StreetInsider.com
Simply Wall St

Returns for OMCL

Cumulative Returns on OMCL

7.2%


10-Year Cumulative Returns

4.0%


7-Year Cumulative Returns

-6.6%


5-Year Cumulative Returns

-11.0%


3-Year Cumulative Returns

Risks for OMCL

What is the probability of a big loss on OMCL?

81.2%


Probability that Omnicell stock will be more than 20% underwater in next one year

51.5%


Probability that Omnicell stock will be more than 30% underwater in next one year.

28.5%


Probability that Omnicell stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does OMCL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Omnicell was unfortunately bought at previous high price.

Drawdowns

Financials for Omnicell

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-2.6%1,2351,2681,2961,3091,2581,1991,1321,070987914892891906924897860836807787772754
Gross Profit-4.2%540564589617604582555529479426413413429449437415402387372364350
Operating Expenses-3.2%575594591569546507465431400383378376377372359340334330328322313
  S&GA Expenses-3.2%476492486470453423389362335315308302301300290274269266263258249
  R&D Expenses-3.1%10010310599.0093.0085.0076.0069.0065.0068.0070.0074.0075.0071.0069.0067.0066.0064.0065.0064.0064.00
EBITDA-100.0%-61.0086.00125127111141--96.0091.0097.00108131131127118----
EBITDA Margin-100.0%-0.05*0.07*0.10*0.10*0.09*0.12*--0.11*0.10*0.11*0.12*0.14*0.15*0.15*0.14*----
Interest Expenses---1.00---2.00---1.00---4.00---7.00--
Earnings Before Taxes5.0%-27.17-28.60-2.4540.0046.0058.0066.0073.0061.0031.0029.0037.0050.0074.0074.0069.0060.0049.0036.0034.0028.00
EBT Margin100.0%--0.02*0.00*0.03*0.04*0.05*0.06*0.07*0.06*0.03*0.03*0.04*0.06*0.08*0.08*------
Net Income-32.0%-23.18-17.576.0048.0061.0072.0078.0080.0060.0035.0032.0038.0049.0069.0061.0054.0048.0038.0038.0054.0048.00
Net Income Margin100.0%--0.01*0.00*0.04*0.05*0.06*0.07*0.07*0.06*0.04*0.04*0.04*0.05*0.08*0.07*------
Free Cashflow-100.0%-60.0030.0010.0038.00123203225222193163124144130129------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-2.5%2,1942,2512,2112,1802,1312,1232,1422,0511,9611,8871,8251,7191,2221,2321,2411,2441,1971,1771,0811,0521,026
  Current Assets-5.7%881935882849788776781889984904829963465478483477430414397379359
    Cash Equivalents17.3%39934033026624526535648261454848662913410412713787.0077.0067.0044.0046.00
  Inventory-7.5%13114114814715013712010410196.0096.0010311411310810610410410199.00104
  Net PPE4.9%10398.0094.0088.0082.0077.0071.0065.0062.0061.0059.0058.0058.0053.0054.0055.0053.0052.0052.0050.0051.00
  Goodwill0.1%736735734731734740739616499499499160335335337335336336336337337
Liabilities-7.0%1,0301,1081,0811,0441,0391,048996940908876857801335353396437424447402433438
  Current Liabilities-18.5%370454428377374951876339317292276234237248237228211211205213202
    LT Debt, Current--------------------18.0018.00
    LT Debt, Non Current---------------50.0077.0077.0097.00135167181
Shareholder's Equity1.8%1,1641,1431,1301,1351,0931,0751,1471,1111,0531,011968918887879845808773730680619589
  Retained Earnings0.9%379376391419402393369355325305291274266270259237217201197183169
  Additional Paid-In Capital1.5%1,0891,0731,0471,0319989831,0251,003971950920892821808781770753725678631613
Shares Outstanding0.3%45.0045.0045.0045.0044.0044.0044.0044.0043.0043.0043.0043.0043.0042.0042.0042.0041.0041.0040.0039.0039.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations77.4%18910778.0055.0077.0015823224924221818614416414414515811711210461.0027.00
  Share Based Compensation-4.7%63.0066.0068.0065.0062.0058.0053.0050.0047.0046.0045.0042.0039.0036.0034.0033.0032.0031.0029.0026.0025.00
Cashflow From Investing-14.9%-61.58-53.58-58.67-233-411-418-412-456-273-279-279-58.08-62.93-58.74-61.66-59.66-58.25-56.53-54.37-52.36-45.22
Cashflow From Financing33.6%20.0015.00-20.95-17.85-8.62-0.3547.0061.00511506456405-54.20-57.07-23.48-3.63-15.73-19.52-13.6029.0038.00
  Buy Backs---52.0052.0052.0052.00--53.0071.0053.00106---------

OMCL Income Statement

2023-06-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues$ 298,973$ 331,386$ 589,602$ 650,214
Cost of revenues164,530173,294330,130342,075
Gross profit134,443158,092259,472308,139
Operating expenses:    
Research and development23,13726,35546,01551,385
Selling, general, and administrative103,558119,252228,672239,185
Total operating expenses126,695145,607274,687290,570
Income (loss) from operations7,74812,485(15,215)17,569
Interest and other income (expense), net4,461(1,711)6,242(1,825)
Income (loss) before income taxes12,20910,774(8,973)15,744
Provision for (benefit from) income taxes8,7581,7052,576(1,538)
Net income (loss)$ 3,451$ 9,069$ (11,549)$ 17,282
Net income (loss) per share:    
Basic (in dollars per share)$ 0.08$ 0.21$ (0.26)$ 0.39
Diluted (in dollars per share)$ 0.08$ 0.20$ (0.26)$ 0.37
Weighted-average shares outstanding:    
Basic (in shares)45,12544,21945,00744,234
Diluted (in shares)45,47246,26045,00747,121
Product revenues    
Revenues$ 188,436$ 233,806$ 374,151$ 459,681
Cost of revenues107,962121,814217,489240,152
Services and other revenues    
Revenues110,53797,580215,451190,533
Cost of revenues$ 56,568$ 51,480$ 112,641$ 101,923

OMCL Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 399,464$ 330,362
Accounts receivable and unbilled receivables, net of allowances of $5,766 and $5,153, respectively273,899299,469
Inventories130,577147,549
Prepaid expenses23,51427,070
Other current assets53,90777,362
Total current assets881,361881,812
Property and equipment, net103,21293,961
Long-term investment in sales-type leases, net35,03932,924
Operating lease right-of-use assets27,69838,052
Goodwill735,523734,274
Intangible assets, net226,707242,906
Long-term deferred tax assets32,76422,329
Prepaid commissions54,77759,483
Other long-term assets96,791105,017
Total assets2,193,8722,210,758
Current liabilities:  
Accounts payable47,19263,389
Accrued compensation52,47573,455
Accrued liabilities145,888172,655
Deferred revenues, net124,602118,947
Total current liabilities370,157428,446
Long-term deferred revenues48,75037,385
Long-term deferred tax liabilities1,5112,095
Long-term operating lease liabilities35,51039,405
Other long-term liabilities6,2656,719
Convertible senior notes, net568,114566,571
Total liabilities1,030,3071,080,621
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued00
Common stock, $0.001 par value, 100,000 shares authorized; 55,488 and 55,030 shares issued; 45,205 and 44,747 shares outstanding, respectively5655
Treasury stock at cost, 10,283 shares outstanding, respectively(290,319)(290,319)
Additional paid-in capital1,088,8251,046,760
Retained earnings379,179390,728
Accumulated other comprehensive loss(14,176)(17,087)
Total stockholders’ equity1,163,5651,130,137
Total liabilities and stockholders’ equity$ 2,193,872$ 2,210,758
Randall A. Lipps
3800
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.